Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.
25 Oct 18:50 · News-Medical